Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
AUROPHARMA:NSE
Aurobindo Pharma Ltd
1.385,60 ₹
-0,80%
(-11,20) 1D
30 apr, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AUROPHARMA...
Açın
1.392,00 ₹
High
1.404,00 ₹
Low
1.378,60 ₹
Mkt. cap
807,02 mlrd
Avg. vol.
1,41 mln
Volume
606,35K
Dividend
0,29%
Quarterly dividend
1,00 ₹
Ex dividend date
8 avq 2025
P/E ratio
23,08
52-wk high
1.459,50 ₹
52-wk low
1.016,10 ₹
EPS
60,04 ₹
Shares outstanding
585,90 mln
No. of employees
28K
News stories
From sources across the web
Profile
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company based in HITEC City, Hyderabad, with U.S. headquarters in East Windsor, Mercer County, New Jersey. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include Pfizer and AstraZeneca. Wikipedia
About Aurobindo Pharma Ltd
CEO-
Employees27,7K
Founded1986
HeadquartersHeydәrabad, Andhra Pradeş, Hindistan
SectorPharmaceutical industry
Websiteaurobindo.com
Last report
9 fev 2026
Fiscal Period
Q3 2026
Normalized EPS / Estimate
16,43/ (15,89 est.)INR
+3,46%beat
Revenue / Estimate
86,46 mlrd/ (84,80 mlrd est.)INR
+1,95%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
83,82 mlrd
78,68 mlrd
82,86 mlrd
86,46 mlrd
Cost of goods sold
38,86 mlrd
32,39 mlrd
33,39 mlrd
34,81 mlrd
Cost of revenue
38,86 mlrd
32,39 mlrd
33,39 mlrd
34,81 mlrd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,34 mlrd
12,29 mlrd
12,77 mlrd
13,10 mlrd
Operating expense
30,73 mlrd
34,31 mlrd
36,98 mlrd
38,56 mlrd
Total operating expenses
69,58 mlrd
66,70 mlrd
70,37 mlrd
73,37 mlrd
Operating income
14,24 mlrd
11,98 mlrd
12,49 mlrd
13,09 mlrd
Other non operating income
-3,02 mlrd
1,05 mlrd
1,16 mlrd
1,54 mlrd
EBT including unusual items
13,35 mlrd
12,07 mlrd
12,76 mlrd
13,39 mlrd
EBT excluding unusual items
13,59 mlrd
12,07 mlrd
12,76 mlrd
14,04 mlrd
Income tax expense
4,32 mlrd
3,83 mlrd
4,28 mlrd
4,29 mlrd
Effective tax rate
32,38%
31,70%
33,53%
32,03%
Other operating expenses
14,53 mlrd
17,97 mlrd
19,91 mlrd
20,81 mlrd
Net income
9,03 mlrd
8,25 mlrd
8,48 mlrd
9,10 mlrd
Net profit margin
10,78%
10,48%
10,24%
10,53%
Earnings per share
15,56
14,20
14,61
16,43
Interest and investment income
3,56 mlrd
-
-
-
Interest expense
-981,70 mln
-977,50 mln
-952,40 mln
-927,70 mln
Net interest expenses
2,58 mlrd
-977,50 mln
-952,40 mln
-927,70 mln
Depreciation and amortization charges
3,86 mlrd
4,06 mlrd
4,29 mlrd
4,65 mlrd
EBITDA
17,86 mlrd
16,10 mlrd
16,66 mlrd
16,71 mlrd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer